Spencer J - Search Results

1

Dual abrogation of MNK and mTOR: a novel therapeutic approach for the treatment of aggressive cancers.

Lineham E, Spencer J, Morley SJ. Lineham E, et al. Among authors: spencer j. Future Med Chem. 2017 Sep;9(13):1539-1555. doi: 10.4155/fmc-2017-0062. Epub 2017 Aug 25. Future Med Chem. 2017. PMID: 28841037 Free article. Review.

2

Therapeutic Potential of Fatty Acid Amide Hydrolase, Monoacylglycerol Lipase, and N-Acylethanolamine Acid Amidase Inhibitors.

Tuo W, Leleu-Chavain N, Spencer J, Sansook S, Millet R, Chavatte P. Tuo W, et al. Among authors: spencer j. J Med Chem. 2017 Jan 12;60(1):4-46. doi: 10.1021/acs.jmedchem.6b00538. Epub 2016 Nov 14. J Med Chem. 2017. PMID: 27766867 Review.

3

Synthesis and biological evaluation of ferrocene-based cannabinoid receptor 2 ligands.

Sansook S, Tuo W, Bollier M, Barczyk A, Dezitter X, Klupsch F, Leleu-Chavain N, Farce A, Tizzard GJ, Coles SJ, Spencer J, Millet R. Sansook S, et al. Among authors: spencer j. Future Med Chem. 2018 Mar 1;10(6):631-638. doi: 10.4155/fmc-2017-0200. Epub 2018 Feb 8. Future Med Chem. 2018. PMID: 29419319 Free article.

4

Special focus: metals in medicine.

Spencer J, Walden B. Spencer J, et al. Future Med Chem. 2018 Mar 1;10(6):607-609. doi: 10.4155/fmc-2018-9999. Future Med Chem. 2018. PMID: 29508658 Free article. No abstract available.

5

Synergistic effects of inhibiting the MNK-eIF4E and PI3K/AKT/ mTOR pathways on cell migration in MDA-MB-231 cells.

Lineham E, Tizzard GJ, Coles SJ, Spencer J, Morley SJ. Lineham E, et al. Among authors: spencer j. Oncotarget. 2018 Jan 31;9(18):14148-14159. doi: 10.18632/oncotarget.24354. eCollection 2018 Mar 6. Oncotarget. 2018. PMID: 29581834 Free PMC article.

6

Probing the Anticancer Action of Novel Ferrocene Analogues of MNK Inhibitors.

Sansook S, Lineham E, Hassell-Hart S, Tizzard GJ, Coles SJ, Spencer J, Morley SJ. Sansook S, et al. Among authors: spencer j. Molecules. 2018 Aug 23;23(9):2126. doi: 10.3390/molecules23092126. Molecules. 2018. PMID: 30142961 Free PMC article.

7

A structure-guided molecular chaperone approach for restoring the transcriptional activity of the p53 cancer mutant Y220C.

Bauer MR, Jones RN, Tareque RK, Springett B, Dingler FA, Verduci L, Patel KJ, Fersht AR, Joerger AC, Spencer J. Bauer MR, et al. Among authors: spencer j. Future Med Chem. 2019 Oct;11(19):2491-2504. doi: 10.4155/fmc-2019-0181. Future Med Chem. 2019. PMID: 31633398 Free PMC article.

8

G-protein coupled receptor and kinase targets: advances in drug discovery from molecular to clinical.

Spencer J. Spencer J. Future Med Chem. 2011 Jul;3(9):1097-100. doi: 10.4155/fmc.11.78. Future Med Chem. 2011. PMID: 21806373 Free article.

9

A cyclodextrin-capped histone deacetylase inhibitor.

Amin J, Puglisi A, Clarke J, Milton J, Wang M, Paranal RM, Bradner JE, Spencer J. Amin J, et al. Among authors: spencer j. Bioorg Med Chem Lett. 2013 Jun 1;23(11):3346-8. doi: 10.1016/j.bmcl.2013.03.084. Epub 2013 Apr 2. Bioorg Med Chem Lett. 2013. PMID: 23591111

10

Biological Effect of a Hybrid Anticancer Agent Based on Kinase and Histone Deacetylase Inhibitors on Triple-Negative (MDA-MB231) Breast Cancer Cells.

Librizzi M, Spencer J, Luparello C. Librizzi M, et al. Among authors: spencer j. Int J Mol Sci. 2016 Jul 30;17(8):1235. doi: 10.3390/ijms17081235. Int J Mol Sci. 2016. PMID: 27483253 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

3,055 results

Search Page